Replies to post #192945 on Biotech Values

[mcbio]

In today’s corporate update, Advaxis CEO O’Connor reported that, as yet, none of the patients in the anal cancer trial have had disease recurrence, with several patients now more than two years post-treatment (in March, Advaxis reported that all 10 of 10 patients in the trial had CRs). He also noted that the historical 3-year recurrence rate for patients similar to those in the Advaxis trial is 45%.

Uncontrolled trial, is it? ; ) Usual caveats apply there. So, the CEO noted patients out past two years of treatment but cited a 3-year recurrence rate? How do you know the disease doesn't typically recur in the third year in this patient population?

[DewDiligence]

ADXS receives EMA ODD for treatment of anal cancer:

http://finance.yahoo.com/news/advaxis-receives-orphan-drug-designation-140500349.html